3rd CDDF Multi-stakeholder workshop on Minimal Residual Disease : AML and CLL

The Third CDDF Multi-Stakeholder Workshop on Minimal Residual Disease: AML and CLL organized by the Cancer Drug Development Forum (CDDF) will take place on 8-9 November 2018 in London, United Kingdom.

CDDF multi-stakeholder workshops on MRD were held in 2014 (breast cancer and haemotological malignancies) and in 2017 (Multiple Myeloma) and generated useful discussions and reports for further developments of the field.

The third edition will now focus on the current status and next steps for the use MRD in AML and CLL clinical trials as well as on open exchange, learning and collaborative search for agreements from regulatory, academic and industry perspectives.

Key points 

• Review of the AML and CLL MRD landscape by leading academic researchers
• Recent developments of clinical and methodological aspects including method valication
• Current status of EMA and FDA regulatory thinking
• How to use MRD as an endpoint in pivotal clinical trials and subsequent regulatory pathways
• Next steps relevant for all stakeholders

Programme committee

• CDDF Board: Axel Glasmacher, John Smyth
• Industry: Davy Chiodin (Acerta/AstraZeneca), Celine Pallaud (Novartis), Irmela Radtke (Roche)
• Regulatory Agencies: To be announced

Target Audience

The target is a multidisciplinary audience of hematologists-oncologists, research scientists, government officials (EMA, FDA, HTA representatives), pharmaceutical industry, assay developers, patient representatives and policymakers.